{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:26:06Z","timestamp":1773689166209,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1053\/j.ajkd.2007.07.023","type":"journal-article","created":{"date-parts":[[2007,10,29]],"date-time":"2007-10-29T14:33:14Z","timestamp":1193668394000},"page":"791-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis"],"prefix":"10.1053","volume":"50","author":[{"given":"Alexander S.","family":"Goldfarb-Rumyantzev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsalan N.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley C.","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lev L.","family":"Barenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred K.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1053\/j.ajkd.2007.07.023_bib1","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"The clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.07.023_bib3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.38793.468449.AE","article-title":"Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials","volume":"332","author":"Costa","year":"2006","journal-title":"BMJ"},{"key":"10.1053\/j.ajkd.2007.07.023_bib4","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.ajkd.2007.07.023_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2007.07.023_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/abbi.1996.0030","article-title":"Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation","volume":"325","author":"Ness","year":"1996","journal-title":"Arch Biochem Biophys"},{"key":"10.1053\/j.ajkd.2007.07.023_bib7","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1046\/j.1523-1755.2002.00324.x","article-title":"Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients","volume":"61","author":"Iseki","year":"2002","journal-title":"Kidney Int"},{"issue":"suppl 12","key":"10.1053\/j.ajkd.2007.07.023_bib8","first-page":"S24","article-title":"Epidemiology of cardiovascular risk factors in chronic renal disease","volume":"9","author":"Coresh","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.07.023_bib9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(12)70364-5","article-title":"Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities","volume":"15","author":"Lowrie","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2007.07.023_bib11","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1093\/ndt\/gfl272","article-title":"The association of lipid levels with mortality in patients on chronic peritoneal dialysis","volume":"21","author":"Habib","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.07.023_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2007.07.023_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2007.07.023_bib14","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2007.07.023_bib15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib16","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/ajkd.2002.33393","article-title":"Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients","volume":"39","author":"Chang","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib17","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1046\/j.1523-1755.2002.00262.x","article-title":"A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD","volume":"61","author":"Harris","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CNP62287","article-title":"Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: A placebo-controlled study","volume":"62","author":"Lins","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2007.07.023_bib19","first-page":"33","article-title":"Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis","volume":"10","author":"Robson","year":"1997","journal-title":"J Nephrol"},{"key":"10.1053\/j.ajkd.2007.07.023_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/ajkd.2002.30547","article-title":"Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis","volume":"39","author":"Saltissi","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.07.023_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1081\/JDI-120013966","article-title":"Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients","volume":"24","author":"Fytili","year":"2002","journal-title":"Ren Fail"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2007.07.023_bib23","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/ajkd.2001.27384","article-title":"Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease","volume":"38","author":"Quaschning","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1046\/j.1523-1755.1999.00375.x","article-title":"Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis","volume":"55","author":"Attman","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/07853899409147902","article-title":"Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients","volume":"26","author":"Horkko","year":"1994","journal-title":"Ann Med"},{"key":"10.1053\/j.ajkd.2007.07.023_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/ndt\/10.4.537","article-title":"Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients","volume":"10","author":"Llopart","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.07.023_bib27","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/089686080202200209","article-title":"Alterations in lipoprotein composition in peritoneal dialysis patients","volume":"22","author":"Moberly","year":"2002","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/0026-0495(91)90120-L","article-title":"Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis","volume":"40","author":"Shoji","year":"1991","journal-title":"Metabolism"},{"key":"10.1053\/j.ajkd.2007.07.023_bib29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/089686089501500410","article-title":"Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis","volume":"15","author":"Siamopoulos","year":"1995","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1046\/j.1523-1755.2002.00175.x","article-title":"Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation","volume":"61","author":"Xue","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib31","series-title":"USRDS 2000 Annual Data Report","year":"2000"},{"key":"10.1053\/j.ajkd.2007.07.023_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0272-6386(99)70188-5","article-title":"Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients","volume":"33","author":"Port","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/089686088700700306","article-title":"Peritoneal equilibration test","volume":"7","author":"Twardowski","year":"1987","journal-title":"Perit Dial Bull"},{"key":"10.1053\/j.ajkd.2007.07.023_bib34","series-title":"Statistical Modeling for Biomedical Researchers","author":"Dupont","year":"2002"},{"key":"10.1053\/j.ajkd.2007.07.023_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1053\/j.ajkd.2007.07.023_bib36","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1093\/ndt\/gfl272","article-title":"The association of lipid levels with mortality in patients on chronic peritoneal dialysis","volume":"21","author":"Habib","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.07.023_bib37","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0306-9877(02)00155-X","article-title":"Hypothesis\u2014The J-shaped follow-up relation between mortality risk and disease risk-factor is due to statistical confounding","volume":"59","author":"Greenberg","year":"2002","journal-title":"Med Hypotheses"},{"key":"10.1053\/j.ajkd.2007.07.023_bib38","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2007.07.023_bib39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5414\/CNP61299","article-title":"Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients","volume":"61","author":"Fox","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2007.07.023_bib40","doi-asserted-by":"crossref","unstructured":"Kwan BC, Beddhu S, Kronenberg F, Cheung AK: Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nat Clin Pract Nephrol 2:76-77, 200","DOI":"10.1038\/ncpneph0101"},{"key":"10.1053\/j.ajkd.2007.07.023_bib41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1523-1755.2002.00109.x","article-title":"HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients","volume":"61","author":"Seliger","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.07.023_bib42","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/pds.1414","article-title":"Parabolas of medication use and discontinuation after myocardial infarction\u2014Are we closing the treatment gap?","volume":"16","author":"Hudson","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1053\/j.ajkd.2007.07.023_bib43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/aje\/kwm070","article-title":"Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect","volume":"166","author":"Brookhart","year":"2007","journal-title":"Am J Epidemiol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607011304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607011304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:48:03Z","timestamp":1759456083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638607011304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0272638607011304"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.07.023","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}